A
0.290
-0.03 (-9.38%)
| Previous Close | 0.320 |
| Open | 0.295 |
| Volume | 10,495 |
| Avg. Volume (3M) | 29,933 |
| Market Cap | 23,174,916 |
| Price / Book | 2.93 |
| 52 Weeks Range | |
| Earnings Date | 27 Aug 2024 - 28 Aug 2024 |
| Diluted EPS (TTM) | -0.210 |
| Total Debt/Equity (MRQ) | 5.65% |
| Current Ratio (MRQ) | 7.34 |
| Operating Cash Flow (TTM) | -15.41 M |
| Levered Free Cash Flow (TTM) | -7.84 M |
| Return on Assets (TTM) | -34.45% |
| Return on Equity (TTM) | -59.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (AU) | Mixed | Mixed |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | ARTRYA FPO [AYA] | - | - |
AIStockmoo Score
-0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.13 |
|
Artrya Ltd is a medical technology company. It is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. The company is managed based on a single segment, being the development of AI-driven CCTA image analysis technology. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 38.94% |
| % Held by Institutions | 4.66% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |